Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020033971 - USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM

Publication Number WO/2020/033971
Publication Date 13.02.2020
International Application No. PCT/US2019/046227
International Filing Date 12.08.2019
Chapter 2 Demand Filed 31.12.2019
IPC
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
C07K 14/65 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
CPC
A61K 31/7024
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7024Esters of saccharides
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/65
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Applicants
  • NEW YORK UNIVERSITY [US]/[US]
Inventors
  • ALBERINI, Cristina, Maria
  • TRAUNER, Dirk
  • ARP, Christopher, James
Agents
  • WATT, Rachel, S.
  • KADLE, Ranjana
  • ROMAN, Paul, J.
  • LOPINSKI, John, D.
  • DIMAIO, John, T. M.
Priority Data
62/717,37210.08.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM
(FR) UTILISATION DE LIGANDS AGONISTES DU RÉCEPTEUR DE L'IGF-2 POUR LE TRAITEMENT DU SYNDROME D'ANGELMAN ET DE L'AUTISME
Abstract
(EN)
Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF -2 receptor. The agonist ligand of IGF-2 receptor may be IGF -2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.
(FR)
L'invention concerne des méthodes de traitement de troubles neurodéveloppementaux, tels que le syndrome d'Angelman et l'autisme, comprenant l'administration à un individu d'une composition comprenant un ligand agoniste du récepteur de l'IGF-2. Le ligand agoniste du récepteur de l'IGF-2 peut être l'IGF-2, ou le mannose-6-phosphate ou un dérivé de celui-ci. L'invention concerne également des compositions comprenant des dérivés de mannose-6-phosphate.
Latest bibliographic data on file with the International Bureau